# BiCAR (NCT04703686)

> Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

No report yet. It can be ordered.

- Drugs tested: glofitamab plus obinutuzumab
- Indication: relapsed/refractory diffuse large B-cell lymphoma after CAR-T therapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04703686
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: The Lymphoma Academic Research Organisation
- Conditions: Diffuse Large B-Cell Lymphoma Refractory; Refractory Indolent Adult Non-Hodgkin Lymphoma; Refractory Transformed B-cell Non-Hodgkin Lymphoma; Refractory Primary Mediastinal Large B-Cell Cell Lymphoma; Refractory Mantle Cell Lymphoma
- Interventions: Obinutuzumab; RO7082859
- Enrollment: 67
- Primary outcome: Overall Survival

## Indexed commentary on BiCAR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=bicar-nct04703686